Last updated on November 2018

A Single-dose Study in Paediatric Subjects Aged 2 to Less Than 18 Years With (sHPT) Receiving Haemodialysis


Brief description of study

This is a multicenter, open-label study to evaluate the safety and pharmacokinetics in pediatric subjects with secondary hyperparathyroidism receiving a single dose of AMG 416 at the end of hemodialysis.

Detailed Study Description

A Single-dose Study to Evaluate the Safety and Pharmacokinetics in Paediatric Subjects Aged 2 to less than 18 Years with (sHPT) Receiving Maintenance Haemodialysis

Clinical Study Identifier: NCT02833857

Contact Investigators or Research Sites near you

Start Over

Amgen Call Center

Research Site
Louisville, KY United States

Amgen Call Center

Research Site
Kansas City, MO United States

Amgen Call Center

Research Site
Bruxelles, Belgium

Amgen Call Center

Research Site
Gent, Belgium

Amgen Call Center

Research Site
Leuven, Belgium

Amgen Call Center

Research Site
Hannover, Germany

Amgen Call Center

Research Site
Heidelberg, Germany

Amgen Call Center

Research Site
Marburg, Germany

Amgen Call Center

Research Site
Vilinus, Lithuania

Amgen Call Center

Research Site
Krakow, Poland

Amgen Call Center

Research Site
London, United Kingdom

Amgen Call Center

Research Site
Los Angeles, CA United States

Amgen Call Center

Research Site
Hamburg, Germany

Amgen Call Center

Research Site
Köln, Germany